基于西斯普拉丁的组合治疗用于癌症
Minerva1, Amrita Bhat1, Sonali Verma1
1ICMR-CAR, School of Biotechnology, SMVDU, Katra, Jammu and Kashmir, India.
Journal of cancer research and therapeutics
|July 20, 2023
概括
西斯 (cis-diamminedichloroplatinum) 是一种关键的化疗药物,通过破坏DNA触发癌细胞死亡. 结合疗法正在探索以提高其有效性和减少癌症治疗中有毒副作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 西斯 (cis-diamminedichloroplatinum) 是一种广泛用于各种固体瘤的化疗剂.
- 它的抗癌活性源于DNA结合和 adduct 形成,诱导亡.
- 然而,由于显著的毒性和获得的耐药性,西斯丁的使用受到限制.
研究的目的:
- 检查基斯普拉丁的作用背后的分子机制.
- 探索旨在克服西斯普拉丁耐药性的组合药物疗法.
- 讨论减轻西斯普拉丁有害毒理影响的策略.
主要方法:
- 关于西斯的分子机制的文献综述.
- 参与西斯胺诱导的亡信号通路的分析 (例如,p53,MAPK,Akt).
- 对组合疗法及其对疗效和毒性影响的研究进行审查.
主要成果:
- 锡斯普拉丁通过DNA损伤和激活应激反应通路诱导亡.
- 药物耐药性机制和毒性 (肝毒性,心毒性,神经毒性) 是一个重大挑战.
- 组合疗法在提高疗效和减少副作用方面表现有前途.
结论:
- 了解西斯的分子作用对于优化癌症治疗至关重要.
- 结合策略对于克服耐药性和管理毒性至关重要.
- 对新型治疗组合的进一步研究可以改善基斯基化疗中患者的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Immunotherapy
560
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
560
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
249
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
249


